Neoadjuvant (pre-surgery) immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → is a growing research area. Phase 2 trials are evaluating anti-PD1 therapy and combinations including nivolumab with cabozantinib for locoregionally advanced melanoma before surgery.
Combining BRAF/MEK inhibition with immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → is being studied in several trials. A Phase 2 study is assessing binimetinib, encorafenib, and pembrolizumab with or without stereotactic radiosurgery in BRAF V600-mutated melanoma with brain metastases.
Adoptive cell therapy approaches are under evaluation, including a Phase 2 trial of tumor-infiltrating lymphocyte (TIL) therapy for metastatic melanoma. Neoantigen-based personalized vaccines combined with nivolumab or pembrolizumab are in Phase 1.
The role of the gut microbiome in immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → response is being actively studied. Phase 2 trials are testing LND101 for fecal microbiota transplantation combined with checkpoint blockade in advanced melanoma, and a separate Phase 2 trial is examining a high-fiber prebiotic diet to enhance immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → outcomes. A Phase 3 study is addressing the practical question of optimal duration of anti-PD-1 therapy in metastatic melanoma.
Where the evidence stands
BRAF/MEK combinations and checkpoint inhibitors, including PD-1 and CTLA-4 blockade, rest on strong Phase 3 evidence. Relatlimab plus nivolumab has Phase 3 support. Neoadjuvant immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → is advancing through Phase 2. TIL therapy has shown promising Phase 2 results. Microbiome modulation and neoantigen vaccines are at Phase 1 to Phase 2. Tebentafusp for uveal melanoma has Phase 3 data in a molecularly defined HLA subtype. The role of combination BRAF/MEK plus immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → in certain high-risk settings is still being defined.
What this means for people affected
Melanoma is one of the cancer types where treatment has advanced most dramatically over recent years, with durable long-term responses achieved in a meaningful proportion of patients with metastatic disease. BRAF mutationA change in DNA sequence that can drive cancer development.Click for full explanation → testing is essential at diagnosis to determine eligibility for targeted therapyDrugs that block specific molecules that cancer cells need to grow.Click for full explanation →. Active research is working to address resistance to immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → and to find better options for rarer subtypes including uveal and mucosal melanoma. Questions about how long to continue immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → and how best to sequence treatments are now active research priorities.
Last updated April 2, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Est. completion: March 1, 2030
Melanoma Trial Investigates Combination Therapy
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the effectiveness of a combination treatment of lifileucel and pembrolizumab for people with untreated advanced melanoma. The trial is currently recruiting participants. The results of this trial will help determine if this combination treatment is a viable option for melanoma patients.
Why it matters: This trial could lead to a new treatment option for people with advanced melanoma.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 1, 2026
Inflammation in Mucosal Tissues May Contribute to Aggressive Melanoma
Researchers studied how the environment around melanoma cells in mucosal tissues affects their behavior. They found that inflammation in these tissues can make melanoma cells more aggressive and resistant to treatment. This could be due to the presence of certain types of immune cells and the activation of specific proteins.
Why it matters: This finding could help scientists understand why some melanoma patients don't respond to treatment and identify new targets for therapy.
Efficacy
Inhibition of HER2/3 by pan-HER inhibitors blocks cell state plasticity and overcomes chemoresistance.
Animal StudyResults in animals only. May or may not apply to humans.Published: March 31, 2026
New Cancer Treatment Combines Two Immune-Boosting Signals
Researchers engineered a virus to deliver two immune signals to cancer cells, aiming to recruit immune cells and fight melanoma. In lab experiments and animal studies, they found that this approach led to deeper and more durable tumor regression. However, more research is needed to confirm these findings.
Why it matters: This study proposes a new strategy for treating immune-cold tumors, which are difficult to target with current cancer therapies.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: November 1, 2028
Testing New Treatments for Advanced Melanoma
Researchers are studying the effectiveness of different treatments for people with advanced melanoma. The trial is comparing the use of a single medication, nivolumab, to a combination of nivolumab and relatlimab, and to another medication, ipilimumab. The trial is currently recruiting participants.
Why it matters: This trial aims to find better treatments for people with advanced melanoma, which can improve their chances of survival and quality of life.
This trial is recruiting participants and is in an early stage of research.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: December 1, 2027
Testing Olaparib and Pembrolizumab for Advanced Uveal Melanoma
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the combination of Olaparib and Pembrolizumab for treating advanced uveal melanoma. The trial is currently recruiting participants. The results of this trial are not yet available.
Why it matters: This trial aims to find a more effective treatment option for people with advanced uveal melanoma.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: November 1, 2029
Testing IL2 and ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → in Advanced Melanoma Patients
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the combination of IL2, ipilimumab, and nivolumab in patients with stage 3 or 4 melanoma. The trial is currently recruiting participants. The results of this study are not yet available.
Why it matters: This trial aims to evaluate the effectiveness of this treatment combination in patients with advanced melanoma.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Est. completion: February 25, 2029
Targeted Alpha Particle Therapy for Metastatic Eye Cancer
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a new treatment for metastatic uveal melanoma, a type of eye cancer that has spread. The treatment involves injecting a small amount of radioactive material directly into the tumor. The trial is currently active but not recruiting participants.
Why it matters: This trial aims to evaluate the safety and effectiveness of targeted alpha particle radiotherapy for patients with metastatic uveal melanoma.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: March 30, 2026
New Gene Signature Predicts Resistance to Cancer Treatment
Researchers analyzed tissue samples from 46 patients with metastatic melanoma to identify a gene signature that could predict resistance to a type of cancer treatment. They found an 82-gene signature that might help doctors predict which patients will not respond to the treatment. This signature was tested in a separate group of patients and showed promise.
Why it matters: This finding could help doctors make more informed decisions about which treatments to use for patients with metastatic melanoma.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: March 28, 2026
New Compounds Show Promise Against Melanoma
Researchers created new versions of a plant-based compound called quercetin and tested them against melanoma cells in the lab. They found that some of these new compounds, called thioquercetins, can kill melanoma cells and may work better when combined with another type of treatment. However, more research is needed to confirm these findings.
Why it matters: This study suggests that new compounds may be useful in developing more effective treatments for melanoma.
Preclinical study, tested on melanoma cells in the lab.
Animal StudyResults in animals only. May or may not apply to humans.Published: March 27, 2026
Dopamine Receptor Targeting May Improve Melanoma Treatment
Researchers used lab experiments to see if targeting a specific receptor in the brain could improve the effectiveness of a treatment for melanoma. They found that in some cases, this approach seemed to work better, but more research is needed to confirm these findings.
Why it matters: This finding could potentially lead to new ways to improve treatment outcomes for patients with advanced melanoma.
This study was conducted in mice and more research is needed to confirm these findings in humans.
PreclinicalLab or cell studies. No human data yet.Est. completion: December 31, 2027
Study Examines Insurance Coverage for Cutaneous Cancer Patients
This observational study is looking at how insurance companies cover treatments for patients with certain types of skin cancer. The study is currently recruiting participants. The results of this study may provide insights into the current state of insurance coverage for these patients.
Why it matters: This study may help researchers understand the challenges patients face when accessing insurance coverage for their skin cancer treatments.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: March 26, 2026
AI Chatbots' Responses to Melanoma Patients' Needs Evaluated
Researchers tested how well leading AI chatbots answered the top concerns of young adults with melanoma. They found that chatbots provided moderately accurate and supportive responses, but their answers were often hard to read and showed limited empathy.
Why it matters: This study highlights the potential and limitations of using AI chatbots to support patients with melanoma.
The study surveyed 152 AYA patients with melanoma, but the sample size is not specified as small.
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
